Misplaced Pages

Part of a series on the
COVID-19 pandemic
COVID-19 (disease) SARS-CoV-2 (virus) Cases Deaths
Timeline 2019 2020 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2021 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2022 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November December 2023
Locations By country and territory Africa Antarctica Asia Europe North America Oceania South America By conveyance Cruise ships Naval ships
International response Endemic phase Evacuations Face masks International aid Origin Lockdowns by country Misinformation by governments Fake treatments Social distancing Software Travel United Nations World Health Organization WTO IP waiver Undercounting of deaths COVID-19 apps Zero-COVID National responses Africa China European Union Germany Ghana India Ireland Netherlands New Zealand Nigeria Philippines Russia Sweden UK government US federal government Vietnam
Medical response Disease testing Breathalyzer Development Drug development Drug repurposing Public health mitigation Vaccines History Research VITT Deployment Authorizations Operation Warp Speed Misinformation and hesitancy US Vaccine card Vaccine passports Current vaccines CoronaVac Covaxin Convidecia Janssen Medigen Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sinopharm BIBP Sputnik V
Variants Variants of concern Alpha Beta Gamma Delta Omicron Other variants Epsilon Zeta Eta Theta Iota Kappa Lambda Mu Cluster 5 Lineage B.1.617
Economic impact and recession Arts and culture Aviation Cannabis Cinema films Disney Fashion Financial markets Food industry Food security Journalism Music Performing arts Retail Shipping Television US sportscasting programs Tourism Video games By country Canada India Ireland Malaysia New Zealand Russia UK US By sport Association football Baseball Basketball Combat sports Cricket Disc golf Gaelic games Gridiron football Ice hockey Motorsport Rugby league
Impacts Long COVID Neurological and psychological symptoms Post-exertional malaise Society Animals Alzheimer's disease patients Black people Crime Death rates by country Disability Domestic violence Emergency evacuations Education Female Environment Hospitals Language LGBT community Long-term care Media coverage Mental health Migration Military Notable deaths Other health issues Popular culture Protests Pregnancy Prisons Religion Catholic Church Hajj Science and technology Social media Strikes Suicides Telehealth Xenophobia and racism Politics Diplomacy Ireland Malaysia New Zealand Russia UK US
COVID-19 portal
v t e

DelNS1-2019-nCoV-RBD-OPT is a COVID-19 vaccine developed by Beijing Wantai Biological, Xiamen University and the University of Hong Kong. It is administered as a single dose intranasal spray.

On 14 December 2022, the vaccine was listed by the National Health Commission of China as a secondary booster dose option for people who have completed their third doses of inactivated COVID-19 vaccines for 6 months or longer.

References

1. "A Study to Evaluate Safety and Immunogenicity of DelNS1-nCoV-RBD LAIV for COVID-19". clinicaltrials.gov. United States National Library of Medicine. 29 April 2021. Retrieved 3 May 2021.
2. "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
3. "China's nasal-spray COVID-19 vaccines undergoing clinical trials: official". Xinhua. 11 June 2021. Retrieved 10 July 2021.
4. "A Phase I Clinical Trial of Influenza virus Vector COVID-19 Vaccine for intranasal Spray (DelNS1-2019-nCoV-RBD-OPT1)". chictr.org.cn. Chinese Clinical Trial Registry. Archived from the original on 7 April 2021. Retrieved 24 March 2021.
5. "A Phase II Clinical Trial of Influenza virus Vector COVID-19 Vaccine for intranasal Spray (DelNS1-2019-nCoV-RBD-OPT1)". chictr.org.cn. Chinese Clinical Trial Registry. Archived from the original on 14 November 2020. Retrieved 24 March 2021.
6. Mi H, Chen Q, Lin H, He T, Zhang R, Ren S, et al. (January 2024). "Short-term effectiveness of single-dose intranasal spray COVID-19 vaccine against symptomatic SARS-CoV-2 Omicron infection in healthcare workers: a prospective cohort study". eClinicalMedicine. 67: 102374. doi:10.1016/j.eclinm.2023.102374. PMC 10758709. PMID 38169940.
7. "关于印发新冠病毒疫苗第二剂次加强免疫接种实施方案的通知" [Notice on the implementation plan for the second dose of new coronavirus vaccine booster vaccination] (in Chinese). National Health Commission. 14 December 2022. Retrieved 14 December 2022.

• Medicine
• Viruses
• COVID-19

This article about COVID-19 vaccines is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

This article about vaccines or vaccination is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Clinical trials related to COVID-19
• Chinese COVID-19 vaccines
• Science and technology in China
• Viral vector vaccines
• Nasal sprays
• COVID-19 vaccine stubs
• Vaccine stubs